New drug combo aims to shield young transplant patients from deadly immune attack

NCT ID NCT03842696

First seen Jan 29, 2026 · Last updated Apr 28, 2026 · Updated 16 times

Summary

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, teens, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vorinostat alongside usual GVHD prevention medicines. The goal is to find the best dose and see if it lowers the chance of developing GVHD, a serious complication where donor cells attack the patient's body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Michigan Health System

    Ann Arbor, Michigan, 48109, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.